A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Condition(s):Multiple MyelomaLast Updated:January 26, 2021Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Multiple MyelomaLast Updated:January 26, 2021Not yet recruiting
Condition(s):HER2-Negative Breast CancerLast Updated:July 21, 2020Recruiting
Condition(s):Stage IV Melanoma; Stage III Melanoma; Advanced MelanomaLast Updated:August 12, 2020Active, not recruiting
Condition(s):Immunotherapy With Pembrolizumab for Nasopharyngeal Carcinoma PatientsLast Updated:March 30, 2021Active, not recruiting
Condition(s):Cancer of Unknown Primary SiteLast Updated:March 1, 2019Recruiting
Condition(s):Ovarian Cancer; Low Grade Serous Carcinoma; Primary Peritoneal Carcinoma; Fallopian Tube CancerLast Updated:February 12, 2021Not yet recruiting
Condition(s):Small Cell Lung CancerLast Updated:February 10, 2020Completed
Condition(s):Cervical CancerLast Updated:November 24, 2020Not yet recruiting
Condition(s):Mucosal Melanoma; Neoadjuvant TreatmentLast Updated:November 13, 2020Not yet recruiting
Condition(s):Melanoma; Non-small Cell Lung CancerLast Updated:September 4, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.